Regenerative Medicine Industry News
Home / Industry News

Industry NewsAccess human allograft tissue and regenerative medicine industry news.

  • 5Apr
    Mikos lab aids new push for regenerative medicine

    Rice University bioengineers led by Antonios Mikos will take part in a five-year, $20 million effort to apply advanced manufacturing techniques to regenerative medicine.

    The goal of the effort led by the Wake Forest Institute for Regenerative Medicine is to speed up the availability of replacement tissue and organs to patients.

    Read More
  • 21Mar
    This is Not a Test: RMAT Designation Goes Live

    The field of regenerative medicine encompasses a wide scope of innovative products including cell therapies, therapeutic tissue engineering products, human cell and tissue products, and certain combination products using such therapies. Examples include genetically-modified cellular therapies, such as chimeric antigen receptor T-cells (CAR-T cells) and human tissues grown on scaffolds for subsequent use. These products hold great promise in addressing serious unmet medical needs. For example, data from a number of different published studies indicate the potential for CAR-T cells to treat certain relapsed or refractory blood cancers.

    Read More
  • 28Dec
    Regenerative medicine is likely game changer for cardiovascular disease

    Regenerative medicine has much to offer the cardiovascular field, although there is still a way to go before it is ready for routine clinical application, according to Andre Terzic, MD, PhD, director of the Mayo Clinic Center for Regenerative Medicine and a professor in Cardiovascular Diseases Research at the Mayo Clinic, in Rochester, Minn.

    Read More
  • 19Nov
    Application of Amniotic Tissue in Orthopedic Surgery

    The use of amniotic tissue in orthopedic surgery has increased in recent years. While more studies are needed to fully understand the therapeutic potential and define the appropriate applications of these tissues, basic science and clinical studies are available that indicate promising results. This review will highlight these studies as they relate to the musculoskeletal system.

    Read More
  • 17Nov
    Demineralized Allografts Market grows with rapidly aging population and increasing obesity rates

    Bone grafts are generally utilized for bone regeneration, pain relief and structure restoration for decades all over the world. Conservatively, autografts were used for bone grafting, in which patient’s own bone was used as a graft. Autologous bone grafts have proven very useful and is recognized as a gold standard for bone transplant. On the contrary, use of autologous bone grafts embraces the risk of infection transfer. This infection transfer during surgical procedures at both tissue harvesting and transplant sites results in late wound healing and prolonged hospital stay. Therefore, allografts were introduced in the market for overcoming the disadvantages associated with autologous grafts. Allografts possess both osteoinductive and osteoconductive properties, and hence serve as a worthy substitute for autografts.

    Read More
  • 8Nov
    The Highs and Lows of Regenerative Medicine

    Nanoscale manipulation on the surface of materials could stimulate cells to differentiate into specific tissues – eliminating the use of growth or transcription factors.

    Researchers are trying to find ways to control cellular response in vitro using engineered materials in a continuous pursuit to regenerate injured or diseased tissues. Recent studies have found that nanoscale structure of the materials, on which such cells are cultured, affect how well they proliferate and develop into the tissues they are meant to become.

    Read More
  • 18Oct
    The Knotty Problem of Bringing Regenerative Medicine to Market

    When Lawrence Summers delivered his last commencement address as Harvard’s president 10 years ago, he spoke of the rosy future for stem cell science and regenerative medicine.

    The advancing technology, he said then, promised a cure for cancer, another for diabetes, a vaccine for Alzheimer’s disease, and ways to control AIDS, any one of which would have enormous impact around the world. Today, he believes he was too pessimistic.

    Read More
  • 1Aug
    Researchers Solve Mystery on How Regenerative Medicine Works

    A study from the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine identifies a mechanism by which bioscaffolds used in regenerative medicine influence cellular behavior, a question that has remained unanswered since the technology was first developed several decades ago. The findings were recently published online in Science Advances.

    Read More
  • 15Jun
    Recent progress in tracking the viability of transplanted stem cells in vivo

    Noninvasive cell-tracking methods are indispensable for assessing the safety and efficacy of stem-cell based therapy. Thus, the research of noninvasive cell-tracking methods for determining in vivo the translocation and long-term viability of the transplanted stem cells have received considerable attention. A recent review article summarized the recent progress in tracking the viability of the transplanted stem cells in vivo. Source: Science China Press

    Read More
  • 3Jun
    New FDA draft guidelines place tighter restrictions on surgical practices using tissue-based regenerative therapies

    The therapeutic use of human cell and tissue products is highly regulated by the U.S. government, but a specific exception allows surgeons to harvest, manipulate, and implant tissues in many commonly performed procedures. Source: News Medical

    Read More
Third Party Sites
The Site may provide hyperlinks to third party websites or access to third party content. This content is NOT intended to characterize SurgiLogix allografts for distribution. SurgiLogix does not control, endorse, or guarantee content found in such sites. You agree that SurgiLogix is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that SurgiLogix shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
  • QUICK LINKS

  • CONTACT US

    (877) 781-4406
    COPYRIGHT © 2016 WWW.SURGILOGIX.COM.
    ALL RIGHTS RESERVED.